Trial · NCT00924664
Adverse events126
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 126
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Tanezumab 10 mg | 6 | 321 | |
| other | Diarrhoea | Gastrointestinal disorders | Tanezumab 20 mg | 18 | 527 | |
| other | Infusion site reaction | General disorders | Tanezumab 10 mg | 12 | 321 | |
| other | Infusion site reaction | General disorders | Tanezumab 20 mg | 17 | 527 | |
| other | Oedema peripheral | General disorders | Tanezumab 10 mg | 11 | 321 | |
| other | Oedema peripheral | General disorders | Tanezumab 20 mg | 32 | 527 | |
| other | Nasopharyngitis | Infections and infestations | Tanezumab 10 mg | 5 | 321 | |
| other | Nasopharyngitis | Infections and infestations | Tanezumab 20 mg | 13 | 527 | |
| other | Sinusitis | Infections and infestations | Tanezumab 10 mg | 12 | 321 | |
| other | Sinusitis | Infections and infestations | Tanezumab 20 mg | 14 | 527 | |
| other | Upper respiratory tract infection | Infections and infestations | Tanezumab 10 mg | 11 | 321 | |
| other | Upper respiratory tract infection | Infections and infestations | Tanezumab 20 mg | 26 | 527 | |
| other | Urinary tract infection | Infections and infestations | Tanezumab 10 mg | 9 | 321 | |
| other | Urinary tract infection | Infections and infestations | Tanezumab 20 mg | 13 | 527 | |
| other | Fall | Injury, poisoning and procedural complications | Tanezumab 10 mg | 7 | 321 | |
| other | Fall | Injury, poisoning and procedural complications | Tanezumab 20 mg | 15 | 527 | |
| other | Muscle strain | Injury, poisoning and procedural complications | Tanezumab 10 mg | 8 | 321 | |
| other | Muscle strain | Injury, poisoning and procedural complications | Tanezumab 20 mg | 17 | 527 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Tanezumab 10 mg | 41 | 321 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Tanezumab 20 mg | 76 | 527 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00924664/events